Novartis has made multiple significant business moves, including a
$2 billion acquisition of immunology biotech Excellergy, marking its second multi-billion dollar transaction in a week. There was an evident rise in its Mumbai-listed shares following an exit deal in India. Its stock has hit an all-time high multiple times, once at $146.4, later at $167.87, $160.21, and then at $153.83. Novartis has also acquired the U.S. biotech firm, Avidity Biosciences, for $12 billion, signaling expansion in the U.S. market.
CEO pay surged 30% subsequent to the record-breaking performance in 2025. Investor sentiment is polarized, with Goldman Sachs warning of an 8% downside due to generics while Madrigal sees sell-off potential. Projections point towards Novartis being a strong long-term value and momentum stock, despite concerns over valuation. Novartis has completed its acquisition plans and is actively investing in innovation, recently dropping $1.7 billion on an AI allergy breakthrough.
Novartis Stocks News Analytics from Mon, 07 Jul 2025 07:00:00 GMT to Sat, 11 Apr 2026 20:55:55 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor -5
